ASH 2022 Post Conference Perspectives: Emerging Treatments in Multiple Myeloma
ASH 2022 Post Conference Perspectives: Evolutions in the Treatment of Myelodysplastic Syndromes (MDS)
Guillermo Garcia-Manero, MD, provides insights surrounding myelodysplastic syndrome (MDS) from the ASH 2022 Annual Meeting and Exposition.
ASH 2022 Post Conference Perspectives: Innovations in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Carlos M. De Castro, MD, provides updates regarding treatment for paroxysmal nocturnal hemoglobinuria (PNH) from the ASH 2022 Annual Meeting and Exposition.
ESMO 2022: Advanced or Metastatic Urothelial Cancer
Arlene Siefker-Radtke, MD, shares key takeaways from her experience at ESMO 2022, focused on advanced or metastatic urothelial cancer.
World Conference on Lung Cancer 2022: Updates in NSCLC
Dr Millie Das, MD discusses updates from the 2022 World Conference on Lung Cancer regarding non-small cell lung cancer (NSCLC).
ASH 2021 Post-Conference Perspectives: Updates in Multiple Myeloma
Expert insight on multiple myeloma management updates from the ASH 2021 annual meeting.
ESC Congress 2021: Updates in Chronic Kidney Disease, Heart Failure, and Type 2 Diabetes
AMCP Post-Conference Perspectives: Chronic Kidney Disease (CKD)
Robert Toto, MD, reviews key takeaways from the 2021 Academy of Managed Care Pharmacy meeting regarding healthcare resource utilization for patients with chronic kidney disease (CKD).
Post Conference Perspective: Immune Checkpoint Inhibitors in Advanced and Metastatic Urothelial Carcinoma
Petros Grivas, MD, PhD, reviews emerging data from the 2021 ASCO GU Virtual Symposium on the role of immune checkpoint inhibitors for the treatment of advanced and metastatic urothelial carcinoma.
ASH 2020 Post Conference Perspectives: Updates in Multiple Myeloma
An expert in the field of multiple myeloma discusses key data releases from ASH 2020.
AHA Post Conference Perspectives: Emerging Therapies in Hypertrophic Cardiomyopathy (HCM)
An expert in the management of hypertrophic cardiomyopathy discusses the burden of disease, existing treatment options, unmet needs, and explores data from an emerging class of agents, myosin inhibitors.
ID Week 2020: Updates in HIV
Infectious disease expert discusses key data releases from ID Week 2020 within the field of HIV care.
The Changing Treatment Landscape of B Cell Malignancies
Navigating the Complex Treatment Landscape of Multiple Myeloma in Transplant Eligible Patients
Perspective Role of Therapy for Multiple Myeloma
2 Clarke Drive Cranbury, NJ 08512